PHASE II STUDY OF PEMETREXED PLUS INTERMITTENT ERLOTINIB COMBINATION THERAPY FOR PRETREATED ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH DOCUMENTATION OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION STATUS

被引：0
|
作者：
Takeuchi, Yoshiko [1 ]
Kijima, Takashi [1 ]
Minami, Seigo [2 ]
Komuta, Kiyoshi [2 ]
Hamaguchi, Masanari [2 ]
Nakatani, Takeshi [2 ]
Koba, Taro [2 ]
Takahashi, Ryo [1 ]
Kida, Hiroshi [1 ]
Nagatomo, Izumi [1 ]
Yamamoto, Suguru [2 ]
Tachibana, Isao [1 ]
Kawase, Ichiro [3 ]
机构：
[1] Osaka Univ, Dept Resp Med Allergy & Rheumat Dis, Grad Sch Med, Suita, Osaka 565, Japan
[2] Osaka Police Hosp, Dept Resp Med, Osaka, Japan
[3] Osaka Prefectural Med Ctr Resp & Allerg Dis, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
pemetrexed; erlotinib; non-small cell lung cancer; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.10-015
引用
收藏
页码：S568 / S568
页数：1
相关论文
共 50 条
  • [21] VeriStrat® and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer
    Padda, Sukhmani K.
    Lara, Primo, Jr.
    Gettinger, Scott N.
    Engelman, Jeffrey A.
    Jaenne, Pasi A.
    West, Howard
    Zhou, Lisa Y.
    Subramaniam, Deepa S.
    Leach, Joseph W.
    Wax, Michael B.
    Neal, Joel W.
    Clary, Douglas O.
    Goodman, Laurie J.
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S291 - S291
  • [22] Combination chemotherapy of intermittent erlotinib with pemetrexed for pretreated patients with advanced non-small cell lung cancer: A phase I dose-finding study.
    Takahashi, Ryo
    Minami, Seigo
    Kijima, Takashi
    Kida, Hiroshi
    Nakatani, Takeshi
    Hamaguchi, Masanari
    Takeuchi, Yoshiko
    Nagatomo, Izumi
    Yamamoto, Suguru
    Tachibana, Isao
    Komuta, Kiyoshi
    Kawase, Ichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] RANDOMIZED PHASE II STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY PEMETREXED IN ADVANCED NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (LOGIK 0904)
    Shiraishi, Yoshimasa
    Inoue, Koji
    Takeshita, Masafumi
    Harada, Taishi
    Tashiro, Naoki
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Takayama, Koichi
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S403 - S404
  • [24] The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced Non-Small Cell Lung Cancer
    Vaguliene, Neringa
    Zemaitis, Marius
    Sarauskas, Valdas
    Vitkauskiene, Astra
    Miliauskas, Skaidrius
    MEDICINA-LITHUANIA, 2012, 48 (04): : 175 - 181
  • [25] PHARMACOGENETIC STUDY OF JAPANESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER TREATED WITH PEMETREXED PLUS CISPLATIN
    Imai, Hisao
    Takahashi, Toshiaki
    Serizawa, Masakuni
    Mori, Keita
    Ono, Akira
    Akamatsu, Hiroaki
    Taira, Tetsuhiko
    Nakamura, Yukiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Koh, Yasuhiro
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1077 - S1077
  • [26] A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Verma, S.
    Malik, P. S.
    Kalra, K.
    Singh, V.
    Kumar, S.
    Khurana, S.
    Pushpam, D.
    Jain, D.
    Gupta, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S130 - S131
  • [27] Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
    Yokoi, Takashi
    Torii, Yoshitaro
    Katashiba, Yuichi
    Sugimoto, Hiroyuki
    Tanijiri, Tsutomu
    Ogata, Makoto
    Inagaki, Noriko
    Kibata, Kayoko
    Hayashi, Mina
    Niki, Maiko
    Shimizu, Toshiki
    Miyara, Takayuki
    Kurata, Takayasu
    Nomura, Shosaku
    ONCOLOGY LETTERS, 2014, 8 (06) : 2453 - 2457
  • [28] Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study
    Tsutani, Y.
    Miyata, Y.
    Masuda, T.
    Fujitaka, K.
    Doi, M.
    Awaya, Y.
    Kuyama, S.
    Kitaguchi, S.
    Ueda, K.
    Okada, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 137 - 137
  • [29] ALK AND EGFR MUTATION ANALYSIS IN A PHASE II TRIAL OF CISPLATIN/PEMETREXED IN JAPANESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Yanagitani, N.
    Kaburaki, K.
    Ohyanagi, F.
    Kudo, K.
    Horiike, A.
    Motoi, N.
    Takeuchi, K.
    Ishikawa, Y.
    Horai, T.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 418 - 418
  • [30] A Phase II Study of Pemetrexed in Heavily Pretreated Non-squamous Non Small Cell Lung Cancer - HANSHIN Oncology Group 001
    Fujita, S.
    Katakami, N.
    Hattori, Y.
    Satouchi, M.
    Uchida, J.
    Imamura, F.
    Yokota, S.
    Kotani, Y.
    Nishimura, T.
    Negoro, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S625 - S625
12345